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Objectives: To assess long-term virological efficacy and the emergence of drug resistance in children who
receive antiretroviral treatment (ART) in rural Tanzania.
Patients and methods: Haydom Lutheran Hospital has provided ART to HIV-infected individuals since 2003.
From February through May 2009, a cross-sectional virological efficacy survey was conducted among children
(,15 years) who had completed ≥6 months of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-
based ART. Genotypic resistance was determined in those with a viral load of .200 copies/mL.
Results: Virological response was measured in 19 of 23 eligible children; 8 of 19 were girls and median age at
ART initiation was 5 years (range 2–14 years). Median duration of ART at the time of the survey was 40 months
(range 11–61 months). Only 8 children were virologically suppressed (≤40 copies/mL), whereas 11 children had
clinically relevant resistance mutations in the reverse transcriptase gene. The most frequent mutations were
M184V (n¼11), conferring resistance to lamivudine and emtricitabine, and Y181C (n¼4), G190A/S (n¼4)
and K103N (n¼4), conferring resistance to NNRTIs. Of concern, three children had thymidine analogue
mutations, associated with cross-resistance to all nucleoside reverse transcriptase inhibitors. Despite wide-
spread resistance, however, only one child experienced a new WHO stage 4 event and none had a CD4 cell
count of ,200 cells/mm3.
Conclusions: Among children on long-term ART in rural Tanzania, .50% harboured drug resistance. Results for
children were markedly poorer than for adults attending the same programme, underscoring the need for
improved treatment strategies for children in resource-limited settings.
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Introduction
Currently, 2.1 million children are living with HIV/AIDS, of whom
90% reside in sub-Saharan Africa. Access to antiretroviral treat-
ment (ART) has increased dramatically over the past years, and
by the end of 2008, 275700 children were receiving ART in
low- and middle-income countries.1
There are numerous obstacles to paediatric ART in resource-
limited settings, including: lack of reliable HIV tests for infants;
limited laboratory capacity to monitor treatment efficacy; vari-
able pharmacokinetics in children; and lack of paediatric anti-
retroviral formulations. Most studies evaluating paediatric ART
in resource-limited settings have been limited by short follow-up
time and few have provided genotypic resistance results.2 – 6
Furthermore, there is a paucity of research from rural settings,
which often face shortages of health workers, transport difficul-
ties and other logistical constraints. Therefore, we aimed to
assess long-term virological efficacy and the emergence of
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drug resistance among children who received first-line ART at a
rural Tanzanian hospital.
Patients and methods
Haydom Lutheran Hospital is a 400 bed hospital located in northern
Tanzania. Since 2003, free ART has been offered to HIV-infected children
in accordance with guidelines from the WHO.7 ART eligibility was based
solely on clinical criteria (WHO paediatric stage 3 or 4) until 2006,
when automated CD4 cell counts became available (FACSCount flow cyt-
ometer, Becton Dickinson, San Jose, CA, USA). First-line treatment com-
prised stavudine or zidovudine, combined with lamivudine, and either
nevirapine or efavirenz. Paediatric second-line treatment was not avail-
able at the time of the survey. After ART initiation, patients were seen
by a clinical officer every 3 months and CD4 cell counts were performed
every 3–6 months.
From February through May 2009, a cross-sectional survey was
carried out among children who had completed ≥6 months of first-line
ART. Children aged ,15 years who presented at the clinic during the
survey period were considered eligible. Ethical approval was granted by
the National Institute for Medical Research (Tanzania) and Regional Com-
mittee for Medical Research Ethics (Norway), and patients or their carers
gave written informed consent to participate in the study.
Plasma specimens for HIV viral load were analysed at Muhimbili
National Hospital, Dar es Salaam, Tanzania, using the COBAS Ampli-
Prep/COBAS TaqMan 48 Analyzer (Roche Diagnostics, Branchburg, NJ,
USA) with a lower detection limit of 40 copies/mL. Specimens with a
viral load of .200 copies/mL were sent to Oslo University Hospital,
Ulleval, Oslo, Norway, for subtyping and genotypic resistance testing
using the ViroSeq HIV-1 Genotyping System (Abbott Molecular, De
Plains, IL, USA). Drug resistance mutations listed in the December 2009
update from the International AIDS Society were considered in this
study.8 Subtyping and resistance profiles to antiretroviral drugs were
interpreted according to the Stanford University HIV Drug Resistance
Database (HIVdb Program, http://hivdb.stanford.edu).
The main outcomes of interest were on-treatment viral suppression
and clinically significant genotypic resistance. Weight-for-age Z-scores
were calculated using software from WHO (WHO AntroPlus for personal
computers, http://www.who.int/growthref/tools/en/). Adherence was
classified as good (.95%), variable (80%–95%) or poor (,80%), based
on clinician estimates. Student t-tests were used to compare mean
CD4 cell counts between those with and without resistance. Logistic
regression was used to study associations between baseline character-
istics and the emergence of drug resistance. Variables with P,0.1 in uni-
variable analyses were selected for multivariable regression analysis.
Data were analysed with SPSS version 16.0 for Windows (SPSS Inc.,
Chicago, IL, USA), except for 95% confidence intervals (CIs) for pro-
portions, which were calculated with NCSS version 2007 (NCSS, Kaysville,
UT, USA). All tests were two-sided and the level of significance was set at
P,0.05.
Results
Of 48 children who enrolled in the HIV programme and started
ART before 1 August 2008, 11 (23%) died, 3 (6%) were lost to
follow-up, 9 (19%) were transferred to another health facility
and 2 (4%) discontinued treatment. Of the remaining 23 children
who were eligible for virological testing, 19 attended the clinic
during the survey period and were included in this study
(Table 1).
Eight of the 19 children were girls and the median age at ART
initiation was 5 years (range 2–14 years). Only eight children
were taken care of by their parents. Most patients had signs
and symptoms of severe immunodeficiency at baseline: 10 chil-
dren were classified as WHO stage 4; 8 as WHO stage 3; and one
as WHO stage 2. Median weight-for-age Z-score was 22.67
(range 25.66 to 20.19) and 9 of 18 had a haemoglobin
level of ,10 g/dL. Only five patients had a pre-ART CD4 cell
count; the median absolute CD4 cell count was 311 cells/mm3
(range 245–426 cells/mm3) and the median CD4% (CD4 cell
count divided by total lymphocyte count) was 11.5% (range
6.1%–21.3%). There were no significant differences between
children who remained in care and those lost to the programme
with regard to gender, age, WHO stage, weight-for-age Z-scores,
haemoglobin or CD4 cell count.
Median duration of ART at the time of the survey was
40 months (range 11–61 months). The initial ART regimen was
zidovudine/lamivudine/nevirapine in seven patients, stavudine/
lamivudine/nevirapine in seven patients, zidovudine/lamivudine/
efavirenz in four patients and stavudine/lamivudine/efavirenz in
one patient. All but one received syrup formulations as part of
their initial regimen. Only one child (Patient 18) had previously
been exposed to antiretroviral drugs through prevention of
mother-to-child transmission interventions.
A plasma viral load result was available in 18 children, of
whom 7 had ≤40 copies/mL (Table 1). In one patient venipunc-
ture failed, but genotyping from dried blood spots succeeded.
Assuming viral suppression in this patient, who had a CD4 cell
count of .2000 cells/mm3 and no drug resistance, still only 8
of 19 patients (42%; 95% CI: 20%–67%) were classified as viro-
logically suppressed.
Eleven plasma samples with a viral load of .200 copies/mL
were genotyped, in addition to the dried blood spot specimen.
HIV-1 subtypes were: A (n¼5); C (n¼3); D (n¼2); CRF01_AE
(n¼1); and inconclusive (n¼1). Eleven of 19 patients (58%;
95% CI: 34%–80%) had clinically relevant resistance mutations
in the reverse transcriptase (RT) gene (Table 1), all of whom had
resistance to both nucleoside reverse transcriptase inhibitors
(NRTIs) and non-nucleoside reverse transcriptase inhibitors
(NNRTIs). None had clinically relevant resistance mutations in
the protease gene. The most frequent RT mutations were
M184V (n¼11), conferring resistance to lamivudine and emtrici-
tabine, and Y181C (n¼4), G190A/S (n¼4) and K103N (n¼4),
conferring resistance to NNRTIs. Of concern, three children
(16%; 95% CI: 3%–40%) had thymidine analogue mutations,
associated with cross-resistance to all NRTIs. Figure 1 gives
the prevalence of drug resistance RT mutations in children, com-
pared with adults from the same programme with ≥30 months
(median 36 months, range 30–53 months) follow-up time on
first-line ART.9
In spite of widespread resistance in .50% of the patients,
only one child experienced a new WHO stage 4 event. CD4 cell
counts at the time of resistance testing (+6 months) were avail-
able for all 19 patients and none had a CD4 cell count of
,200 cells/mm3. However, mean CD4 cell count was signifi-
cantly lower in patients with resistance compared with those
without resistance (596 versus 1114 cells/mm3; P¼0.018).
Only adherence was significantly associated with emergence
of drug resistance (poor/variable versus good; odds ratio 12.0;
95% CI: 1.3–111.3; P¼0.029). No significant associations were
found for sex, age, WHO stage, weight-for-age Z-score, haemo-
globin level, total lymphocyte count, carer (parents versus
others) or duration of ART. Since all patients with viral non-
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Table 1. Genotypic resistance results for 19 HIV-infected children on long-term ART, Haydom Lutheran Hospital, Tanzania
ID
no. Sex
Age at
ART start
(years) ART regimen: initial (currenta)
Duration of
ART (months)
Most recent CD4
cell count
(cells/mm3)b
Viral load
(copies/mL) NRTI mutations NNRTI mutations
Resistance to
antiretroviral drugs
1 M 6 ZDV/3TC/EFV (d4T/3TC/NVP) 40 595 640000 M184V V108I, Y181CV 3TC, FTC, all NNRTIs
2 M 7 d4T/3TC/NVP 11 667 300000 M184V G190S 3TC, FTC, all NNRTIs
3 M 5 ZDV/3TC/NVP (d4T/3TC/NVP) 18 650 220000 D67N, K70R, M184V,
T215Y, K219EQ
K101E, Y181C, G190A all NRTIs and NNRTIs
4 M 11 d4T/3TC/NVP 58 550 28000 V75I, M184V, T215Y K103N, V108I all NRTIs, NVP, EFV
5 M 3 d4T/3TC/NVP 59 575 23000 M184V K101E, G190A 3TC, FTC, all NNRTIs
6 M 5 ZDV/3TC/EFV (d4T/3TC/NVP) 25 899 6400 M184V Y181C 3TC, FTC, all NNRTIs
7 F 2 ZDV/3TC/NVP 35 748 5000 M184V Y181C 3TC, FTC, all NNRTIs
8 F 4 d4T/3TC/NVP (ZDV/3TC/EFV) 56 264 1200 D67N, K70R, M184V,
L210W, T215F, K219Q
V179T, G190A all NRTIs and NNRTIs
9 M 14 d4T/3TC/EFV (d4T/3TC/NVP) 37 398 980 M184V K103N, V108I 3TC, FTC, NVP, EFV
10 M 8 d4T/3TC/NVP 54 713 870 M184V K103N 3TC, FTC, NVP, EFV
11 F 2 ZDV/3TC/NVP (d4T/3TC/NVP) 36 496 350 A64V, M184V V90I, K103N 3TC, FTC, NVP, EFV
12 F 2 ZDV/3TC/NVP (ZDV/3TC/EFV) 27 .2000 NDc none none none
13 M 5 ZDV/3TC/NVP (d4T/3TC/NVP) 51 820 40 — — —
14 F 9 d4T/3TC/NVP 61 712 ,40 — — —
15 M 10 ZDV/3TC/NVP (d4T/3TC/NVP) 53 800 ,40 — — —
16 F 5 ZDV/3TC/EFV (d4T/3TC/NVP) 43 1261 ,40 — — —
17 F 5 ZDV/3TC/EFV (d4T/3TC/NVP) 40 1050 ,40 — — —
18 F 3 ZDV/3TC/NVP (d4T/3TC/EFV) 23 1599 ,40 — — —
19 M 5 d4T/3TC/NVP 11 672 ,40 — — —
d4T, stavudine; ZDV, zidovudine; 3TC, lamivudine; FTC, emtricitabine; NVP, nevirapine; EFV, efavirenz.
aOnly specified if different from initial regimen.
bWithin+6 months of viral load/resistance testing.
cND, not done; venipuncture failed and dried blood spots were used for resistance testing.
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suppression also had resistance, and vice versa, the same analy-
sis also applies to predictors of viral non-suppression.
Discussion
Only 42% of the children in this study had a suppressed HIV
viral load and .50% harboured drug resistance after a median
of 40 months on first-line ART. These results were markedly
poorer than for adults attending the same clinic, of whom 15%
had drug resistance after 3–4 years on first-line ART.9
Only a few previous studies have reported long-term
virological results of paediatric ART in Africa. Rouet et al.10
found that only 46.5% of children had a suppressed viraemia
(,300 copies/mL) after 42 months on mainly protease inhibitor-
based ART in Abidjan, Coˆte d’Ivoire. In contrast, Davies et al.11
recently reported excellent treatment outcomes in a large pae-
diatric multicentre cohort in South Africa, with viral suppression
(,400 copies/mL) in 82.4% of children after 3 years on ART.
Our study, however, is the first to describe long-term resistance
results from a rural African paediatric ART programme. The resist-
ance pattern observed in our cohort, with high-level resistance to
lamivudine and NNRTIs in patients with viral non-suppression, is
similar to recent data from paediatric cohorts in Thailand and
China,5,6,12 and might provide a useful forecast of drug resistance
and demand for second-line paediatric antiretroviral drugs in
resource-limited settings in the coming years.
In the present study, the smaller children were prescribed
syrups and/or tablets, whereas those .15 kg received an adult
fixed-dose combination tablet divided into halves and quarters.
Both these approaches have serious weaknesses. The syrup for-
mulations may be difficult to administer correctly, foul tasting,
require refrigeration and have short shelf-lives once opened.7
With regard to the use of adult fixed-dose combination tablets,
accurate cutting can be difficult to achieve. Moreover, the ratio
between the three drugs is not suitable for paediatric use, since
children have a faster nevirapine metabolism than adults.13
Given the low genetic barrier of the NNRTIs, selection of resistance
can occur rapidly in patients with suboptimal adherence or
reduced serum concentrations. Poor adherence was a strong
and significant predictor of resistance in our study, and, hence,
in order to promote adherence, it is imperative to increase
access to fixed-dose combination tablets specifically designed
for children. This should include a variety of drug combinations,
including regimens based on ritonavir-boosted protease inhibitors,
for which the genetic barrier to resistance is higher.
There were certain limitations to our study. First, the study
was small and the estimates of drug resistance have wide CIs.
Second, the lack of objective measures of adherence was a
weakness of our study design. Third, there was a selection bias
of older children, who represent long-time non-progressors
with a better prognosis and whose adherence might differ
from younger children. On the other hand, since ART initiation
was based mostly on clinical criteria, there was a selection bias
towards more advanced immunodeficiency at baseline, which
increases the risk of drug resistance. However, these biases
reflect the realities in many African ART programmes.2 – 4,10,11
Finally, this was a cross-sectional survey of patients alive and
in care, leaving out a high number of patients who died,
were lost to follow-up or transferred out; hence, our data
cannot be extrapolated to all patients starting ART. Nevertheless,
we managed to include 19 of 23 eligible children and, thus, we
believe our results are representative of children who receive
long-term ART in this setting.
In conclusion, we found an alarmingly high prevalence of
drug resistance among children who received long-term ART in
rural Tanzania. Results for children were markedly poorer than
for adults attending the same clinic. Improved treatment strat-
egies for children, such as access to a variety of fixed-dose com-
bination tablets for all age groups, should be prioritized in the
global efforts to scale-up ART in resource-limited settings.
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Figure 1. Proportion (%) of children on ART who harboured drug resistance mutations in the RT gene. For comparison, adults from the same
programme with ≥30 months (median 36 months, range 30–53 months) follow-up time on first-line ART are shown.9 TAMs, thymidine analogue
mutations.
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